Samir Kumar-Singh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2139297/publications.pdf

Version: 2024-02-01

108	9,472	57631 44	42291 92
papers	citations	h-index	g-index

125	125	125	11066
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Host Immunity Influences the Composition of Murine Gut Microbiota. Frontiers in Immunology, 2022, 13, 828016.	2.2	11
2	Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis. Journal of Clinical Medicine, 2022, 11, 1494.	1.0	2
3	Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients. Clinica Chimica Acta, 2022, 531, 4-11.	0.5	8
4	Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 1862-1872.	1.3	23
5	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. Microorganisms, 2022, 10, 1021.	1.6	13
6	Identification of Potential Urinary Metabolite Biomarkers of Pseudomonas aeruginosa Ventilator-Associated Pneumonia. Biomarker Insights, 2022, 17, 117727192210991.	1.0	1
7	Neuropathological Changes in Nakalanga Syndromeâ€"A Case Report. Pathogens, 2021, 10, 116.	1.2	2
8	Cytokines and Onchocerciasis-Associated Epilepsy, a Pilot Study and Review of the Literature. Pathogens, 2021, 10, 310.	1.2	2
9	The Secretome of Filarial Nematodes and Its Role in Host-Parasite Interactions and Pathogenicity in Onchocerciasis-Associated Epilepsy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 662766.	1.8	17
10	Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection. Nature Communications, 2021, 12, 2460.	5.8	47
11	Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. European Journal of Cancer, 2021, 148, 328-339.	1.3	14
12	Serotonin Levels in the Serum of Persons with Onchocerciasis-Associated Epilepsy: A Case-Control Study. Pathogens, 2021, 10, 720.	1.2	3
13	Evaluation of GeneXpert PA assay compared to genomic and (semi-)quantitative culture methods for direct detection of Pseudomonas aeruginosa in endotracheal aspirates. Antimicrobial Resistance and Infection Control, 2021, 10, 110.	1.5	2
14	No Evidence for the Involvement of Leiomodin-1 Antibodies in the Pathogenesis of Onchocerciasis-Associated Epilepsy. Pathogens, 2021, 10, 845.	1.2	16
15	A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity. JCI Insight, 2021, 6, .	2.3	23
16	Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients. Cancers, 2021, 13, 5718.	1.7	10
17	Onchocerca volvulus is not detected in the cerebrospinal fluid of persons with onchocerciasis-associated epilepsy. International Journal of Infectious Diseases, 2020, 91, 119-123.	1.5	30
18	Inhibition of Aquaporin 4 Decreases Amyloid Aî²40 Drainage Around Cerebral Vessels. Molecular Neurobiology, 2020, 57, 4720-4734.	1.9	32

#	Article	IF	Citations
19	Comparison of Diagnostic Tests for Onchocerca volvulus in the Democratic Republic of Congo. Pathogens, 2020, 9, 435.	1.2	15
20	BacPipe: A Rapid, User-Friendly Whole-Genome Sequencing Pipeline for Clinical Diagnostic Bacteriology. IScience, 2020, 23, 100769.	1.9	31
21	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). PLoS ONE, 2020, 15, e0231555.	1.1	8
22	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
23	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
24	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
25	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
26	Mechanical Ventilation Impairs IL-17 Cytokine Family Expression in Ventilator-Associated Pneumonia. International Journal of Molecular Sciences, 2019, 20, 5072.	1.8	12
27	Neuroinflammation and Not Tauopathy Is a Predominant Pathological Signature of Nodding Syndrome. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1049-1058.	0.9	44
28	Hypersynchronicity in the default mode-like network in a neurodevelopmental animal model with relevance for schizophrenia. Behavioural Brain Research, 2019, 364, 303-316.	1.2	11
29	Comparison of GeneXpert MRSA/SA ETA assay with semi-quantitative and quantitative cultures and nuc gene-based qPCR for detection of Staphylococcus aureus in endotracheal aspirate samples. Antimicrobial Resistance and Infection Control, 2019, 8, 4.	1.5	25
30	Mechanical Ventilation Induces Interleukin 4 Secretion in Lungs and Reduces the Phagocytic Capacity of Lung Macrophages. Journal of Infectious Diseases, 2018, 217, 1645-1655.	1.9	5
31	Methods to Investigate the Molecular Basis of Progranulin Actions on Brain and Behavior In Vivo Using Knockout Mice. Methods in Molecular Biology, 2018, 1806, 233-253.	0.4	1
32	Proposal for assignment of allele numbers for mobile colistin resistance (mcr) genes. Journal of Antimicrobial Chemotherapy, 2018, 73, 2625-2630.	1.3	101
33	CD8 signaling in microglia/macrophage M1 polarization in a rat model of cerebral ischemia. PLoS ONE, 2018, 13, e0186937.	1.1	47
34	Tetraspanin 6: a pivotal protein of the multiple vesicular body determining exosome release and lysosomal degradation of amyloid precursor protein fragments. Molecular Neurodegeneration, 2017, 12, 25.	4.4	70
35	^{99m}Tc-Duramycin SPECT Imaging of Early Tumor Response to Targeted Therapy: A Comparison with¹⁸F-FDG PET. Journal of Nuclear Medicine, 2017, 58, 665-670.	2.8	38
36	In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp.. Frontiers in Cellular and Infection Microbiology, 2017, 7, 106.	1.8	193

#	Article	IF	Citations
37	Biofilm-Induced Type 2 Innate Immunity in a Cystic Fibrosis Model of Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology, 2017, 7, 274.	1.8	19
38	Animal models of hospital-acquired pneumonia: current practices and future perspectives. Annals of Translational Medicine, 2017, 5, 132-132.	0.7	29
39	The endotracheal tube microbiome associated with Pseudomonas aeruginosa or Staphylococcus epidermidis. Scientific Reports, 2016, 6, 36507.	1.6	51
40	P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy. Neuropharmacology, 2016, 105, 175-185.	2.0	57
41	Consolidating and Exploring Antibiotic Resistance Gene Data Resources. Journal of Clinical Microbiology, 2016, 54, 851-859.	1.8	94
42	Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Eurosurveillance, 2016, 21, .	3.9	648
43	Fractal Analysis in Neurodegenerative Diseases. Springer Series in Computational Neuroscience, 2016, , 233-249.	0.3	3
44	Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. Neurobiology of Disease, 2015, 82, 526-539.	2.1	69
45	Comparison of Biofilm Formation between Major Clonal Lineages of Methicillin Resistant Staphylococcus aureus. PLoS ONE, 2014, 9, e104561.	1.1	43
46	Hypolocomotive behaviour associated with increased microglia in a prenatal immune activation model with relevance to schizophrenia. Behavioural Brain Research, 2014, 258, 179-186.	1.2	93
47	The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model. Brain, Behavior, and Immunity, 2014, 42, 138-146.	2.0	114
48	Overexpression of ALS-Associated p.M337V Human TDP-43 in Mice Worsens Disease Features Compared to Wild-type Human TDP-43 Mice. Molecular Neurobiology, 2013, 48, 22-35.	1.9	83
49	Characterization of Two New CTX-M-25-Group Extended-Spectrum Î²-Lactamase Variants Identified in Escherichia coli Isolates from Israel. PLoS ONE, 2012, 7, e46329.	1.1	8
50	Cellular ageing, increased mortality and FTLDâ€TDPâ€associated neuropathology in progranulin knockout mice. Journal of Pathology, 2012, 228, 67-76.	2.1	102
51	Fractal analysis of amyloid plaques in Alzheimer's disease patients and mouse models. Neurobiology of Aging, 2011, 32, 1579-1587.	1.5	14
52	Progranulin and TDP-43: Mechanistic Links and Future Directions. Journal of Molecular Neuroscience, 2011, 45, 561-573.	1.1	51
53	Pathological Validation of Animal Models of Dementia. Neuromethods, 2011, , 99-141.	0.2	1
54	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	3.9	854

#	Article	IF	Citations
55	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
56	Increased caspase activation and decreased TDPâ€43 solubility in progranulin knockout cortical cultures. Journal of Neurochemistry, 2010, 115, 735-747.	2.1	57
57	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
58	TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3858-3863.	3.3	491
59	Identification of 2 Loci at Chromosomes 9 and 14 in a Multiplex Family With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Archives of Neurology, 2010, 67, 606-16.	4.9	47
60	Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology, 2009, 73, 626-632.	1.5	84
61	Hereditary and Sporadic Forms of AÎ²-Cerebrovascular Amyloidosis and Relevant Transgenic Mouse Models. International Journal of Molecular Sciences, 2009, 10, 1872-1895.	1.8	31
62	Antibody Elution Method for Multiple Immunohistochemistry on Primary Antibodies Raised in the Same Species and of the Same Subtype. Journal of Histochemistry and Cytochemistry, 2009, 57, 567-575.	1.3	112
63	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	3.9	377
64	Progranulin expression correlates with denseâ€core amyloid plaque burden in Alzheimer disease mouse models. Journal of Pathology, 2009, 219, 173-181.	2.1	75
65	Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. Genes, Brain and Behavior, 2008, 7, 67-82.	1.1	78
66	Reduced brain volumes in mice expressing APP-Austrian mutation but not in mice expressing APP-Swedishâ€“Austrian mutations. Neuroscience Letters, 2008, 447, 143-147.	1.0	4
67	Intraneuronal amyloid Î² and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. Neurobiology of Aging, 2008, 29, 241-252.	1.5	52
68	Molecular Pathogenesis of Frontotemporal Lobar Degeneration. Archives of Neurology, 2008, 65, 700-4.	4.9	2
69	A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain, 2007, 130, 2277-2291.	3.7	56
70	Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions: A Molecular Genetic Update. Neurodegenerative Diseases, 2007, 4, 227-235.	0.8	21
71	Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family. Archives of Neurology, 2007, 64, 1436.	4.9	143
72	Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches. Neurodegenerative Diseases, 2007, 4, 349-365.	0.8	64

#	Article	IF	Citations
73	Frontotemporal Lobar Degeneration: Current Concepts in the Light of Recent Advances. Brain Pathology, 2007, 17, 104-114.	2.1	66
74	Genetics and pathology of alpha-secretase site AÎ²PP mutations in the understanding of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 389-398.	1.2	6
75	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 2006, 442, 920-924.	13.7	1,386
76	Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased AÎ²42 and decreased AÎ²40. Human Mutation, 2006, 27, 686-695.	1.1	306
77	Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Human Mutation, 2006, 27, 888-896.	1.1	62
78	Characterization of Ubiquitinated Intraneuronal Inclusions in a Novel Belgian Frontotemporal Lobar Degeneration Family. Journal of Neuropathology and Experimental Neurology, 2006, 65, 289-301.	0.9	45
79	Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology, 2006, 66, S86-S92.	1.5	40
80	Progranulin Mutations in Ubiquitin-Positive Frontotemporal Dementia Linked to Chromosome 17q21. Current Alzheimer Research, 2006, 3, 485-491.	0.7	60
81	Tau is central in the genetic Alzheimerâ€“frontotemporal dementia spectrum. Trends in Genetics, 2005, 21, 664-672.	2.9	55
82	Dense-Core Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer's Disease Are Centered on Vessel Walls. American Journal of Pathology, 2005, 167, 527-543.	1.9	168
83	A novel presenilin 1 mutation associated with Pick's disease but not ?-amyloid plaques. Annals of Neurology, 2004, 55, 617-626.	2.8	210
84	A novel drug target in Alzheimer's disease. Lancet, The, 2004, 364, 1738-1739.	6.3	7
85	Hereditary cerebral hemorrhage with amyloidosis dutch type (AÎ²PP 693): decreased plasma amyloid-Î² 42 concentration. Neurobiology of Disease, 2003, 14, 619-623.	2.1	37
86	Dense-Core Senile Plaques in the Flemish Variant of Alzheimer's Disease Are Vasocentric. American Journal of Pathology, 2002, 161, 507-520.	1.9	108
87	In Vitro Studies of Flemish, Dutch, and Wild-Type Î²-Amyloid Provide Evidence for Two-Staged Neurotoxicity. Neurobiology of Disease, 2002, 11, 330-340.	2.1	44
88	Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. Brain, 2001, 124, 2383-2392.	3.7	70
89	Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Human Molecular Genetics, 2001, 10, 1665-1671.	1.4	178
90	Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-? concentrations. Annals of Neurology, 2000, 48, 806-808.	2.8	135

#	Article	IF	Citations
91	Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation. Brain, 2000, 123, 2467-2474.	3.7	28
92	Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692). Brain, 2000, 123, 2130-2140.	3.7	51
93	Behavioral Disturbances without Amyloid Deposits in Mice Overexpressing Human Amyloid Precursor Protein with Flemish (A692G) or Dutch (E693Q) Mutation. Neurobiology of Disease, 2000, 7, 9-22.	2.1	100
94	Nonfibrillar diffuse amyloid deposition due to a gamma42-secretase site mutation points to an essential role for N-truncated Abeta42 in Alzheimer's disease. Human Molecular Genetics, 2000, 9, 2589-2598.	1.4	135
95	Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PSâ€1 mutations that lead to exceptionally high amyloidâ€Î² concentrations. Annals of Neurology, 2000, 48, 806-808.	2.8	3
96	Computer-assisted differential diagnosis of malignant mesothelioma based on syntactic structure analysis. , 1999, 35, 23-29.		38
97	Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF ? expression. , 1999, 189, 72-78.		176
98	Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF Î² expression. , 1999, 189, 72.		1
99	Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. , 1998, 186, 300-305.		98
100	Transforming growth factor-Î², basement membrane components and heparan sulphate proteoglycans in experimental hepatic schistosomiasis mansoni. Cell and Tissue Research, 1998, 292, 101-106.	1.5	18
101	Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. , 1998, 186, 300.		2
102	WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TOp53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL-TYPE TRANSITION, AND PROGNOSIS. , 1997, 181, 67-74.		112
103	EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA. , 1997, 182, 211-216.		76
104	WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELLâ€TYPE TRANSITION, AND PROGNOSIS. Journal of Pathology, 1997, 181, 67-74.	2.1	6
105	Evaluation and prognostic value of DNA content and of morphometric parameters in malignant mesothelioma using digital image analysis. Lung Cancer, 1996, 14, 229-237.	0.9	4
106	GlutathioneS-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study. Journal of Cancer Research and Clinical Oncology, 1996, 122, 619-624.	1.2	17
107	Detection of numerical chromosomal aberrations in paraffin-embedded malignant pleural mesothelioma by non-isotopicin situ hybridization. Journal of Pathology, 1995, 175, 219-226.	2.1	11
108	Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 631-634.	1.4	20